KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Evolent Health (EVH) over the last 11 years, with Q3 2025 value amounting to -$8.8 million.

  • Evolent Health's Cash from Investing Activities rose 5558.82% to -$8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$102.3 million, marking a year-over-year decrease of 10857.83%. This contributed to the annual value of -$62.9 million for FY2024, which is 8485.55% up from last year.
  • As of Q3 2025, Evolent Health's Cash from Investing Activities stood at -$8.8 million, which was up 5558.82% from -$60.5 million recorded in Q2 2025.
  • Evolent Health's 5-year Cash from Investing Activities high stood at $46.0 million for Q1 2021, and its period low was -$395.0 million during Q1 2023.
  • Moreover, its 5-year median value for Cash from Investing Activities was -$9.7 million (2024), whereas its average is -$44.0 million.
  • As far as peak fluctuations go, Evolent Health's Cash from Investing Activities soared by 52519.66% in 2021, and later crashed by 1408181.31% in 2022.
  • Evolent Health's Cash from Investing Activities (Quarter) stood at -$54.4 million in 2021, then skyrocketed by 91.8% to -$4.5 million in 2022, then crashed by 35.82% to -$6.1 million in 2023, then tumbled by 229.31% to -$19.9 million in 2024, then surged by 56.04% to -$8.8 million in 2025.
  • Its Cash from Investing Activities stands at -$8.8 million for Q3 2025, versus -$60.5 million for Q2 2025 and -$13.1 million for Q1 2025.